J&J | JNJ - Interest Expense On Debt


J&J reported $43M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Abbott USD 299M 231M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Baxter International USD 78M 20M Mar/2026
Bayer EUR 675M 87M Dec/2025
Becton, Dickinson and Co. USD 132M 17M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
Boston Scientific USD 96M 6M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
CONMED USD 7.88M 823K Jun/2026
Cooper Companies USD 20.9M 1.5M Mar/2026
Dexcom USD 3.1M 1.1M Mar/2026
Edwards Lifesciences USD 30M 5.9M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Globus Medical USD 5.49B 48.7M Jun/2026
Insulet USD 11M 3.7M Jun/2026
Integra LifeSciences USD 22.99M 529K Jun/2026
Intuitive Surgical USD 20.88B 765.6M Jun/2026
J&J USD 43M 25M Mar/2026
Medtronic USD 176M 5M Mar/2026
Merck USD 525M 46M Jun/2026
Merit Medical Systems USD 12.12M 5.59M Jun/2026
Novartis USD 462M 119M Jun/2026
Pfizer USD 667M 4M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Stryker USD 47.93B 1.64B Jun/2026
Tandem Diabetes Care USD 1.15B 808K Jun/2026
Teva Pharmaceutical Industries USD 195M 21M Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Zimmer Biomet Holdings USD 22.8B 22.73B Jun/2026
Zoetis USD 61M 1000K Jun/2026